Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 563 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Investigators Choice Clear all
Recruiting Not applicable Interventional

Healthy Lifestyles for Bipolar Disorder

NCT06188754
View directory record Official record
Conditions
Time Restricted Eating, Diet, Mediterranean
Interventions
Time restricted eating, Mediterranean diet
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 4, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 4, 2026, 5:30 PM EDT
Completed Not applicable Interventional

Use Of Gigstride Device In Patients With Lower Extremity Deficit

NCT06548087
View directory record Official record
Conditions
Ambulation Difficulty, Lower Extremity Problem
Interventions
Gigstride Ambulatory Device
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 4, 2026, 5:30 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical and Molecular Biomarker Studies in RAI1 (Retinoic Acid-Induced 1) -Related Disorders

NCT06274164
View directory record Official record
Conditions
RAI1 Gene 17P11.2 Deletion+Duplication
Interventions
Electroencephalography/Polysomnography (EEG/PSG), Skin Biopsy, Blood draw
Diagnostic Test · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 80 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 4, 2026, 5:30 PM EDT
Completed Not applicable Interventional

MRI/MRSI in Risk Assessment of Prostate Cancer Patients

NCT00582543
View directory record Official record
Conditions
Prostate Cancer
Interventions
eMRI/MRSI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2011 · Synced Sep 4, 2026, 5:30 PM EDT
Not yet recruiting Not applicable Interventional

Circadian Light Exposure Adjustment for Restfulness

NCT07391852
View directory record Official record
Conditions
Sleep Onset Latency
Interventions
Amber Tinted Glasses, Clear Glasses, Smart Lightbulbs
Device
Lead sponsor
University of Arizona
Other
Eligibility
60 Months to 83 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 4, 2026, 5:30 PM EDT
Terminated No phase listed Observational

17-OHPC in Pregnancy: IM vs SC Routes

NCT04183452
View directory record Official record
Conditions
Preterm Birth
Interventions
17-Hydroxyprogesterone Caproate 250 mg IM Dose, 17-Hydroxyprogesterone Caproate 275 mg SC Dose
Drug
Lead sponsor
Steve N. Caritis, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Newark, Delaware • Durham, North Carolina • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Sep 4, 2026, 5:30 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Preparedness Through Respiratory Virus Epidemiology and Community Engagement

NCT07147517
View directory record Official record
Conditions
Respiratory Infection Virus, COVID -19, RSV, FLU
Interventions
Component A0, Component A1, Component A2, Component B
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
La Jolla, California • San Ysidro, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 4, 2026, 5:30 PM EDT
Completed Not applicable Interventional

Prematurity Related Ventilatory Control (PRE-VENT) - Specific Aim 3

NCT03333174
View directory record Official record
Conditions
Infant,Premature
Interventions
Cardiorespiratory monitoring
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 98 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Sep 4, 2026, 5:30 PM EDT
Completed Phase 1 Interventional

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

NCT04299880
View directory record Official record
Conditions
Oncology
Interventions
Napabucasin, Nab-paclitaxel, Gemcitabine, Nivolumab, Paclitaxel, Irinotecan, Leucovorin, 5Fluorouracil, Bevacizumab
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Scarborough, Maine • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 4, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

NCT02023879
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 4, 2026, 5:30 PM EDT
Withdrawn Phase 2 Interventional

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

NCT06060587
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, ADT, Abiraterone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 4, 2026, 5:30 PM EDT
Recruiting Phase 1 Interventional

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

NCT05270213
View directory record Official record
Conditions
Advanced Cancer
Interventions
RBS2418, Pembrolizumab, Other approved anti-cancer therapy
Drug
Lead sponsor
Riboscience, LLC.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 4, 2026, 5:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Respecting the Circle of Life on Pregnancy Prevention Outcomes Among American Indian Adolescents

NCT02904629
View directory record Official record
Conditions
Sex, Unprotected Sex, Contraception, Alcohol Use, Drug Use, Pregnancy
Interventions
Respecting the Circle of Life (RCL), Control Program
Behavioral · Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
11 Years and older
Enrollment
1,072 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 4, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Results available

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

NCT04995029
View directory record Official record
Conditions
Moderate to Severe Opioid-use Disorder
Interventions
Transmucosal Buprenorphine, Extended-release Buprenorphine
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
785 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
28
States / cities
Garden Grove, California • Panorama City, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 4, 2026, 5:30 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

AB Gait Estim Neurophysiology

NCT06430164
View directory record Official record
Conditions
Gait
Interventions
Gait Training, Functional electrical stimulation (FES), Peripheral electrical stimulation paired with cortical magnetic stimulation pulses
Other · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 4, 2026, 5:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Southwest Hub for American Indian Youth Suicide Prevention Research

NCT03543865
View directory record Official record
Conditions
Suicide, Surveillance, Mental Health, Substance Use, Depressive Symptoms
Interventions
New Hope (NH), Elders Resilience (ER), Case Management (CM)
Behavioral · Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
16 Years to 29 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 4, 2026, 5:30 PM EDT
Recruiting Phase 3 Interventional

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657
View directory record Official record
Conditions
Relapsed Refractory Multiple Myeloma
Interventions
AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib, Pomalidomide
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
48
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 4, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

NCT04632992
View directory record Official record
Conditions
Advanced Unresectable or Metastatic Solid Malignancy
Interventions
Entrectinib, Inavolisib, Alectinib, Ipatasertib, Atezolizumab, Trastuzumab Emtansine, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Tucatinib, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, Pralsetinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
38
States / cities
Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 4, 2026, 5:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing Gait Automaticity in Older Adults by Exploiting Locomotor Adaptation

NCT04934956
View directory record Official record
Conditions
Community Mobility of Older Adults, Locomotor Adaptability, Gait Automaticity
Interventions
Split-belt walking, Multiple transitions between split-belt and tied-belt walking
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
19 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 4, 2026, 5:30 PM EDT
Active, not recruiting Not applicable Interventional

Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight

NCT04002440
View directory record Official record
Conditions
Efficacy, Safety Issues
Interventions
AMIA with SHARESOURCE Connectivity Platform, HomeChoice PRO
Combination Product · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Chula Vista, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 4, 2026, 5:30 PM EDT
Terminated Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

NCT04832854
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Gemcitabine, Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Duarte, California • Los Angeles, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 4, 2026, 5:30 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

EXD-959 Orthodontic Brackets and EXD-961 Related Instruments Trial

NCT03606551
View directory record Official record
Conditions
Malocclusion
Interventions
EXD-959 Bracket System
Device
Lead sponsor
3M
Industry
Eligibility
11 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
5
States / cities
Culver City, California • Wellington, Florida • Northfield, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 4, 2026, 5:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery

NCT05130801
View directory record Official record
Conditions
Breast Cancer
Interventions
pHLIP® ICG NIRF imaging
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Montvale, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 4, 2026, 5:30 PM EDT